/REVB
REVB Stock - Revelation Biosciences, Inc.
Healthcare|BiotechnologyNASDAQ
$0.89-0.87%
$0.01 (-0.87%) • Dec 19
55
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.0
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).70
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.100
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+10.0%upside
Target: $0.98
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for REVB
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$0.88 – $0.90
TARGET (TP)$1.03
STOP LOSS$0.82
RISK/REWARD1:1.9
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta-0.10
52W High$60.48
52W Low$0.83
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A |
| Gross Margin | N/A | N/A | N/A | N/A | N/A |
| Operating Income | $-7,975,109 | $-8,656,664 | $-10,864,511 | $-11,950,485 | $-3,795,819 |
| Net Income | $-15,038,536 | $-120,254 | $-10,829,549 | $-11,986,837 | $-3,795,693 |
| Net Margin | N/A | N/A | N/A | N/A | N/A |
| EPS | $-87.68 | $-8.41 | $-9643.37 | $-20400.00 | $-9032.69 |
Company Overview
Revelation Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immune system therapeutics and diagnostics. The company engages in developing therapeutic product candidates, including REVTx-99b that is in a Phase Ib clinical trial for the prevention or treatment of chronic nasal congestion and allergic rhinitis; and REVTx-200, a nonclinical stage product for intranasal therapy. It is also involved in developing REVTx-300, a non-clinical stage product that is being developed as a potential therapy for the treatment of chronic organ disease, including chronic kidney disease and non-alcoholic steatohepatitis; and REVDx-501, a rapid test kit, which is a point of care in vitro diagnostic test that has the potential to detect respiratory viral infections, such as SARS-CoV-2, Influenza A, Influenza B, parainfluenza, or respiratory syncytial virus. The company was founded in 2020 and is based in San Diego, California.
Visit WebsiteLoading analyst ratings...
Earnings History & Surprises
REVBBeat Rate
60%
Last 15 quarters
Avg Surprise
-6.1%
EPS vs Estimate
Beats / Misses
9/6
Last 12 quarters
Latest EPS
$-1.77
Q4 2025
EPS Surprise History
Q1 24
+23.9%
$-133.28vs$-175.04
Q2 24
+54.4%
$-39.36vs$-86.24
Q3 24
+14.9%
$-24.64vs$-28.96
Q4 24
+70.4%
$-13.44vs$-45.44
Q1 25
-55.6%
$-4.98vs$-3.20
Q2 25
+69.3%
$-6.33vs$-20.64
Q3 25
-57.2%
$-7.01vs$-4.46
Q4 25
-32.1%
$-1.77vs$-1.34
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 6, 2026 | — | — | — | — |
Q1 2026 | Mar 5, 2026 | $-0.92 | — | — | — |
Q4 2025 | Nov 6, 2025 | $-1.34 | $-1.77 | -32.1% | ✗ MISS |
Q3 2025 | Aug 7, 2025 | $-4.46 | $-7.01 | -57.2% | ✗ MISS |
Q2 2025 | May 8, 2025 | $-20.64 | $-6.33 | +69.3% | ✓ BEAT |
Q1 2025 | Mar 6, 2025 | $-3.20 | $-4.98 | -55.6% | ✗ MISS |
Q4 2024 | Nov 8, 2024 | $-45.44 | $-13.44 | +70.4% | ✓ BEAT |
Q3 2024 | Aug 9, 2024 | $-28.96 | $-24.64 | +14.9% | ✓ BEAT |
Q2 2024 | May 10, 2024 | $-86.24 | $-39.36 | +54.4% | ✓ BEAT |
Q1 2024 | Mar 22, 2024 | $-175.04 | $-133.28 | +23.9% | ✓ BEAT |
Q4 2023 | Nov 9, 2023 | $-144.14 | $-197.00 | -36.7% | ✗ MISS |
Q3 2023 | Aug 11, 2023 | $-158.56 | $-120.12 | +24.2% | ✓ BEAT |
Q2 2023 | May 22, 2023 | $-312.31 | $-245.05 | +21.5% | ✓ BEAT |
Q1 2023 | Mar 30, 2023 | $-840.84 | $-850.45 | -1.1% | ✗ MISS |
Q4 2022 | Nov 10, 2022 | $-1512.00 | $-1008.00 | +33.3% | ✓ BEAT |
Q3 2022 | Aug 15, 2022 | $-2352.00 | $-2016.00 | +14.3% | ✓ BEAT |
Q2 2022 | May 16, 2022 | $-4.90 | $-16.45 | -235.7% | ✗ MISS |
Q2 2022 | Apr 15, 2022 | — | $-486.32 | — | — |
Q4 2021 | Oct 29, 2021 | — | $-351.38 | — | — |
Q3 2021 | Aug 23, 2021 | — | $-285.03 | — | — |
Latest News
Revelation Biosciences Announces The FDA Has Accepted Its End-Of-Phase 1 Meeting Package For Gemini, Its Acute Kidney Injury Treatment Candidate
📈 PositiveBenzinga•Nov 20, 2025, 02:05 PM
Revelation Biosciences Q3 EPS $(1.77) Misses $(1.33) Estimate
📉 NegativeBenzinga•Nov 6, 2025, 10:12 PM
Revelation Biosciences shares are trading lower after the company announced the immediate exercise of 4.63 million warrants at $2.20 per share.
📉 NegativeBenzinga•Sep 11, 2025, 01:25 PM
Revelation Biosciences Announces Immediate Exercise Of 4.36M Warrants At $2.20/Share
📈 PositiveBenzinga•Sep 11, 2025, 12:35 PM
Revelation Biosciences Reports Gemini Significantly Reduced Inflammatory Activity And Restored Normal Cellular Response In Stage 3 And 4 CKD Patients
📈 PositiveBenzinga•Sep 10, 2025, 11:25 AM
Revelation Biosciences shares are trading lower. The company announced safety and activity data for Phase 1 PRIME study.
📉 NegativeBenzinga•Sep 9, 2025, 03:49 PM
Revelation Biosciences Announces Safety And Activity Data For Phase 1b PRIME Study; Gemini Normalized The Inflammatory Response At The Cellular Level In Stage 3 And 4 CKD Patients
📈 PositiveBenzinga•Sep 9, 2025, 12:06 PM
Frequently Asked Questions about REVB
What is REVB's current stock price?
Revelation Biosciences, Inc. (REVB) is currently trading at $0.89 per share. The stock has moved -0.87% today.
What is the analyst price target for REVB?
No analyst price targets are currently available for this stock.
What sector is Revelation Biosciences, Inc. in?
Revelation Biosciences, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is REVB's market cap?
Revelation Biosciences, Inc. has a market capitalization of $0.01 billion, making it a small-cap company.
Does REVB pay dividends?
No, Revelation Biosciences, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorATXI
Avenue Therapeutics, Inc.
$0.65
Mkt Cap: $0.0B
AZTR
Azitra, Inc.
$0.29
Mkt Cap: $0.0B
GTBP
GT Biopharma, Inc.
$0.76
Mkt Cap: $0.0B
INDP
Indaptus Therapeutics, Inc.
$2.03
Mkt Cap: $0.0B
NKGN
NKGen Biotech, Inc. Common Stock
$0.05
Mkt Cap: $0.0B
ONCO
Onconetix, Inc.
$1.77
Mkt Cap: $0.0B
PBM
Psyence Biomedical Ltd.
$1.00
Mkt Cap: $0.0B
SLRX
Salarius Pharmaceuticals, Inc.
$0.69
Mkt Cap: $0.0B
SLXN
Silexion Therapeutics Ltd.
$2.40
Mkt Cap: $0.0B
SPRC
SciSparc Ltd.
$1.46
Mkt Cap: $0.0B
Explore stocks similar to REVB for comparison